BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Soficitinib (ICP-332) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Soficitinib (ICP-332)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06775860-1392@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Soficitinib (ICP-332): Phase 3 readout est. (NCT06775860)
DESCRIPTION:Soficitinib (ICP-332)\, phase 3\, Atopic Dermatitis.\nStudy: IC
 P-332 in Subjects With Moderate to Severe Atopic Dermatitis\nEstimated pri
 mary completion: 25 November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/soficitinib-icp-332#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06775860
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07236099-1392@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Soficitinib (ICP-332): Phase 2 readout est. (NCT07236099)
DESCRIPTION:Soficitinib (ICP-332)\, phase 2.\nStudy: Study of the Efficacy 
 and Safety of ICP-332 in Participants With Prurigo Nodularis\nEstimated pr
 imary completion: March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/soficitinib-icp-332#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07236099
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07378527-1392@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Soficitinib (ICP-332): Phase 2/3 readout est. (NCT07378527)
DESCRIPTION:Soficitinib (ICP-332)\, phase 2/3.\nStudy: Study of the Efficac
 y and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
 \nEstimated primary completion: September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07378527
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047612-1392@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Soficitinib (ICP-332): Phase 2/3 readout est. (NCT07047612)
DESCRIPTION:Soficitinib (ICP-332)\, phase 2/3.\nStudy: ICP-332 in Subjects 
 With Non-segmental Vitiligo\nEstimated primary completion: April 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/soficitinib-icp-332#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07047612
URL:https://assetmemo.bio/drug/soficitinib-icp-332#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
